Thermo Fisher Scientific (TMO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this maker of scientific instrument and laboratory supplies have returned +8.2% over the past month versus the Zacks S&P 500 composite's +4.4% change. The Zacks Medical - Instruments industry, to which Thermo Fisher belongs, has gained 6.2% over this period. Now the key questio ...

In the latest market close, Thermo Fisher Scientific (TMO) reached $597.25, with a -0.36% movement compared to the previous day. This change lagged the S&P 500's daily gain of 1.12%. Meanwhile, the Dow experienced a rise of 0.61%, and the technology-dominated Nasdaq saw an increase of 1.54%.Shares of the maker of scientific instrument and laboratory supplies have appreciated by 9.61% over the course of the past month, outperforming the Medical sector's gain of 2.49% and the S&P 500's gain of 2.06%.The inves ...

Thermo Fisher Scientific (TMO) announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). The new registry, which is open to enrollment, is CorEvitas’ 10th syndicated disease registry and addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.For investors’ note, Thermo Fisher’s August 2021 acquisition of CorEvitas has expanded the company’s Laboratory Products and Biopharma Services segmen ...

The latest trading session saw Thermo Fisher Scientific (TMO) ending at $591.50, denoting a +1.18% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 0.51%. Meanwhile, the Dow experienced a rise of 0.2%, and the technology-dominated Nasdaq saw an increase of 0.58%.The maker of scientific instrument and laboratory supplies's shares have seen an increase of 4.34% over the last month, surpassing the Medical sector's gain of 2.54% and the S&P 500's gain of 2.94%.Analysts and in ...

Thermo Fisher Scientific Inc. (NYSE:TMO) TD Cowen 44th Annual Health Care Conference March 6, 2024 9:10 AM ET Company Participants Marc Casper - Chairman, President and CEO Conference Call Participants Dan Brennan - TD Cowen Dan Brennan Great. Welcome, Day 3 of the TD Cowen Global Healthcare Conference, 44th Annual. I'm Dan Brennan, I cover tools, diagnostics here. Really pleased to be joined with me on stage here, Marc Casper, Chairman, President and CEO of Thermo Fisher. So, Marc, welcome. Marc Casper Tha ...

A month has gone by since the last earnings report for Thermo Fisher Scientific (TMO) . Shares have added about 3.3% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Thermo Fisher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Thermo Fisher Q4 Earnings Top Estimat ...

Thermo Fisher Scientific (TMO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this maker of scientific instrument and laboratory supplies have returned +3.3% over the past month versus the Zacks S&P 500 composite's +5.2% change. The Zacks Medical - Instruments industry, to which Thermo Fisher belongs, has gained 4.9% over this period. Now the key questio ...

Financial Performance - Revenues for 2023 were $42,857 million, a decrease of 5% compared to $44,915 million in 2022[147]. - GAAP operating income for 2023 was $6,859 million, down 18% from $8,393 million in 2022, resulting in a GAAP operating income margin of 16.0%[147]. - Adjusted operating income (non-GAAP) decreased by 11% to $9,810 million in 2023, with an adjusted operating income margin of 22.9%[147]. - Organic revenue growth was reported at (5)%, with a 1% positive impact from acquisitions[149]. - Sales of COVID-19 testing products were $0.33 billion in 2023, significantly down from $3.11 billion in 2022[150]. - Life Sciences Solutions segment revenues fell by 26% to $9,977 million, with segment income decreasing by 39% to $3,420 million[159]. - Analytical Instruments segment revenues increased by 10% to $7,263 million, with segment income rising by 27% to $1,908 million[160]. - Specialty Diagnostics segment revenues decreased by 8% to $4,405 million, while segment income increased by 10% to $1,124 million[161]. - Laboratory Products and Biopharma Services segment revenues grew by 2% to $23,041 million, with segment income increasing by 17% to $3,358 million[163]. Cash Flow and Debt - As of December 31, 2023, cash and cash equivalents totaled $8,077 million, a decrease from $8,524 million in 2022[172]. - Total debt increased to $34,917 million in 2023 from $34,488 million in 2022[172]. - Net cash provided by operating activities was $8,406 million in 2023, down from $9,154 million in 2022[175]. - Free cash flow for 2023 was reported at $7,014 million, compared to $6,935 million in 2022[194]. - The company has a revolving credit facility providing up to $5,000 million, with no borrowings outstanding as of December 31, 2023[174]. Acquisitions and Stock Repurchase - The company spent $2,700 million on the acquisition of The Binding Site Group and $910 million on CorEvitas, LLC in 2023[180]. - The company repurchased $3,000 million of its common stock (5.2 million shares) during 2023[182]. Tax and Valuation - The company expects its GAAP effective tax rate for 2024 to be between 4% and 6%, with an adjusted tax rate of approximately 10.5%[167]. - The liability for unrecognized tax benefits was $0.54 billion at December 31, 2023, down from $0.57 billion in 2022[202]. - The company's tax valuation allowance remained at $1.32 billion as of December 31, 2023[207]. Goodwill and Intangible Assets - Goodwill and indefinite-lived intangible assets totaled $44.02 billion and $1.24 billion, respectively, as of December 31, 2023[198]. - The company recorded definite-lived intangible asset impairments of $0.01 billion in 2023[201]. - The company performed quantitative goodwill impairment tests and found no impairments at the end of the tenth fiscal month of 2023[199]. Currency and Interest Rate Impact - A 100 basis point decrease in interest rates would increase the fair value of the company's debt by approximately $2.33 billion[210]. - A 10% depreciation in year-end 2023 functional currencies relative to the U.S. dollar would reduce shareholders' equity by approximately $1.26 billion[212]. - A 10% depreciation in non-functional currency exchange rates related to forward currency-exchange contracts would result in an unrealized loss of $43 million[214]. - A 10% depreciation in non-functional currency exchange rates applied to certain cash balances would negatively impact net income by $13 million[215]. Earnings Per Share - The adjusted diluted earnings per share (EPS) for 2023 was $21.55, down from $23.24 in 2022[192]. - The adjusted operating income for 2023 was $9,810 million, with an adjusted operating income margin of 22.9%, compared to $10,985 million and 24.5% in 2022[192]. Capital Expenditures - The company expects capital expenditures for property, plant, and equipment to be between $1,300 million and $1,500 million for 2024[181].

Thermo Fisher Scientific, Inc. (TMO) recently introduced a new instrument for Ion chromatography to enhance labs' functional adaptability, efficiency, and reliability -- Thermo Scientific Dionex Inuvion Ion Chromatography (IC) system. The new system will make ion analysis simpler and more intuitive for labs of all sizes.The recent launch will bolster Thermo Fisher’s Analytical Instrument segment.More on New LaunchThe Dionex Inuvion system helps labs operate more effectively by providing simply adjustable wo ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...